Anti-fibrotic properties

Anti-fibrotic properties refer to the pharmacological ability of a substance to prevent, arrest, or reverse fibrosis, which is the pathological accumulation of excess extracellular matrix (ECM) components like collagen in response to chronic injury (NCBI Bookshelf, NBK541031). This term describes a therapeutic outcome or drug attribute rather than a specific molecular target such as a receptor or enzyme. In clinical practice, anti-fibrotic agents are primarily used to treat interstitial lung diseases, liver cirrhosis, and chronic kidney disease by targeting pathways that drive myofibroblast activation and ECM deposition (PubMed: 29439603). Typical drugs exhibiting these properties, such as Pirfenidone and Nintedanib, act on diverse signaling networks including the TGF-beta pathway and various receptor tyrosine kinases (StatPearls: Idiopathic Pulmonary Fibrosis). Because fibrosis is a complex multicellular process involving inflammation and tissue repair, achieving anti-fibrotic properties often requires modulating multiple cell types, including fibroblasts, macrophages, and epithelial cells. Consequently, research focuses on identifying specific molecular targets (e.g., TGFB1, CTGF, or integrins) that can be pharmacologically inhibited to yield the desired anti-fibrotic effect.

Other names

Antifibrotic activityFibrosis inhibitionAnti-fibrotic effect

Not applicable as a single molecular mechanism. Anti-fibrotic properties are achieved through various mechanisms including the inhibition of transforming growth factor-beta (TGF-beta) signaling, blockade of tyrosine kinase receptors (PDGFR, VEGFR, FGFR), and reduction of fibroblast proliferation and collagen synthesis (PMID: 30650310).